Changing therapeutic paradigms in castrate-resistant prostate cancer

Clinical Genitourinary Cancer

Volumn 8, Issue 1, 2010, Pages 17-22

  Zivi, Andrea ^a,b   Massard, Christophe ^a,b   De Bono, Johann ^a,b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Abiraterone; Androgen receptor; CRPC; MDV 3100

Indexed keywords

4 [3 [4 CYANO 3 (TRIFLUOROMETHYL)PHENYL] 5,5 DIMETHYL 4 OXO 2 THIOXO 1 IMIDAZOLIDINYL] 2 FLUORO N METHYLBENZAMIDE; ABIRATERONE; ARN 509; BMS 641988; CYTOCHROME P450 17; HE 3235; HEAT SHOCK PROTEIN; OGX 427; PREDNISOLONE; PREDNISONE; TAK 700; TOK 001; UNCLASSIFIED DRUG;

APPARENT MINERALOCORTICOID EXCESS SYNDROME; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL TRIAL (TOPIC); DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FLUID RETENTION; HUMAN; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SEIZURE; SIDE EFFECT; STEROID THERAPY; TREATMENT OUTCOME;

EID: 78651081213     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.3816/CGC.2010.n.003     Document Type: Review

References (31)

1. Fitzpatrick JM, Anderson J, Sternberg CN, et al. Optimizing treatment for men with advanced prostate cancer: Expert recommendations and the multidisciplinary approach. Crit Rev Oncol Hematol 2008; 68(suppl 1):S9-22.
2. Reid AH, Attard G, Barrie E, et al. CYP17 inhibition as a hormonal strategy for prostate cancer. Nat Clin Pract Urol 2008; 5:610-20.
3. Attard G, Cooper CS, de Bono JS. Steroid hormone receptors in prostate cancer: A hard habit to break? Cancer Cell 2009; 16:458-62.
4. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med 2003; 349:366-81 Review.
5. Fizazi K, Massard C. New agents in metastatic prostate cancer. Eur J Cancer 2009; 45(suppl 1):379-80.
6. Chen Y, Clegg NJ, Scher HI. Anti-androgens and androgen-depleting therapies in prostate cancer: New agents for an established target. Lancet Oncol 2009; 10:981-9.
7. Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004; 10:33-9.
8. Knudsen KE, Scher HI. Starving the addiction: New opportunities for durable suppression of AR signaling in prostate cancer. Clin Cancer Res 2009; 15:4792-8.
9. Barrie SE, Potter GA, Goddard PM, et al. Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase). J Steroid Biochem Mol Biol 1994; 50:267-73.
10. Potter GA, Barrie SE, Jarman M, et al. Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase- C17,20-lyase): Potential agents for the treatment of prostatic cancer. J Med Chem 1995; 38:2463-71.
11. Rowlands MG, Barrie SE, Chan F, et al. Esters of 3-pyridylacetic acid that combine potent inhibition of 17 alpha-hydroxylase/C17,20-lyase (cytochrome P45017 alpha) with resistance to esterase hydrolysis. J Med Chem 1995; 38:4191-7.
12. Attard G, Reid AH, Yap TA, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008; 26:4563-71.
13. Attard G, Reid AH, A'Hern R, et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 2009; 27:3742-8.
14. Ryan CJ, Smith MR, Fong L, et al. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol 2010; 28:1481-8.
15. Reid AH, Attard G, Danila DC, et al. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol 2010; 28:1489-95.
16. Danila DC, Morris MJ, de Bono JS, et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol 2010; 28:1496-501.
17. de Bono JS, Logothetis CJ, Fizazi K, et al. Abiraterone acetate (AA) plus low dose prednisone or prednisone improves overall survival (OS) in patients with metastatic castration resistant prostate cancer who have progressed after docetaxel-based chemotherapy: Results of COU-AA-301, a randomized double-blind placebo-controlled phase III study. Presented at: The 2010 European Society for Medical Oncology meeting. Abstract LBA5.
18. Dreicer R, Agus DB, MacVicar GR, et al. Safety, pharmacokinetics, and efficacy of TAK-700 in metastatic castration-resistant prostate cancer: A phase I/II, open-label study. J Clin Oncol 2010; 28(15 suppl):254s (abstract 3084).
19. Dreicer R, Agus DB, MacVicar GR, et al. Safety, pharmacokinetics, and efficacy of TAK-700 in castration-resistant, metastatic prostate cancer: A phase I/II, open-label study. Presented at: The 2010 Genitourinary Cancers Symposium. Abstract 103.
20. Montgomery RB, Morris MJ, Ryan CJ, et al. HE3235, a synthetic adrenal hormone, in patients with castration-resistant prostate cancer (CRPC): Clinical phase I/II trial results. Presented at: The 2010 Genitourinary Cancers Symposium. Abstract 235.
21. Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009; 324:787-90.
22. Scher HI, Beer TM, Higano CS, et al; Prostate Cancer Foundation/ Department of Defense Prostate Cancer Clinical Trials Consortium. Antitumour activity of MDV3100 in castration-resistant prostate cancer: A phase 1-2 study. Lancet 2010; 375:1437-46.
23. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351:1502-12.
24. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351:1513-20.
25. Kuroda K, Liu H, Kim S, et al. Docetaxel down-regulates the expression of androgen receptor and prostate-specific antigen but not prostate-specific membrane Antigen in prostate cancer cell lines: Implications for PSA surrogacy. Prostate 2009; 69:1579-85.
26. Gan L, Chen S, Wang Y, et al. Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer. Cancer Res 2009; 69:8386.
27. Attard G, Swennenhuis JF, Olmos D, et al. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res 2009; 69:2912-8.
28. Jhavar S, Brewer D, Edwards S, et al. Integration of ERG gene mapping and gene-expression profiling identifies distinct categories of human prostate cancer. BJU Int 2009; 103:1256-69.
29. Attard G, Clark J, Ambroisine L, et al. Transatlantic Prostate Group. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene 2008; 27:253-63.
30. Taplin ME. Drug insight: Role of the androgen receptor in the development and progression of prostate cancer. Nat Clin Pract Oncol 2007; 4:236-44.
31. Attard G, Colin SC, de Bono JS. Steroid hormone receptors in prostate cancer: A hard habit to break? Cancer Cell 2009; 16:458-62.